@article {Chawner2020.01.14.20017426, author = {Samuel J.R.A. Chawner and Joanne L. Doherty and Richard Anney and Kevin M. Antshel and Carrie E. Bearden and Raphael Bernier and Wendy K. Chung and Caitlin C. Clements and Sarah R. Curran and Goran Cuturilo and Ania M. Fiksinski and Louise Gallagher and Robin P. Goin-Kochel and Leila Kushan and Raquel E. Gur and Ellen Hanson and Sebastien Jacquemont and Wendy R. Kates and Anne M. Maillard and Donna M. McDonald-McGinn and Marina Mihaljevic and Judith S Miller and Hayley Moss and Milica Pejovic-Milovancevic and Robert T. Schultz and LeeAnne Green-Snyder and Jacob A. Vorstman and Tara L. Wenger and IMAGINE-ID Consortium and Jeremy Hall and Michael J. Owen and Marianne B.M. van den Bree}, title = {A Genetics-First Approach to Dissecting the Heterogeneity of Autism: Phenotypic Comparison of Autism Risk Copy Number Variants}, elocation-id = {2020.01.14.20017426}, year = {2020}, doi = {10.1101/2020.01.14.20017426}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective Certain copy number variants (CNVs) greatly increase risk of autism. We conducted a genetics-first study to investigate whether heterogeneity in the clinical presentation of autism is underpinned by specific genotype-phenotype relationships.Methods This international study included 547 individuals (12.3 years (SD=4.2), 54\% male) who were ascertained on the basis of having a genetic diagnosis of a rare CNV associated with high risk of autism (82 16p11.2 deletion carriers, 50 16p11.2 duplication carriers, 370 22q11.2 deletion carriers and 45 22q11.2 duplication carriers), as well as 2027 individuals (9.1 years (SD=4.9), 86\% male) with autism of heterogeneous aetiology. The Autism Diagnostic Interview-Revised (ADI-R) and IQ testing were conducted.Results The four genetic variant groups differed in autism severity, autism subdomain profile as well as IQ profile. However, we found substantial variability in phenotypic outcome within individual genetic variant groups (74\% to 97\% of the variance depending on the trait), whereas variability between groups was low (1\% to 21\% depending on trait). We compared CNV carriers who met autism criteria, to individuals with heterogeneous autism, and a range of profile differences were identified. Using clinical cut-offs, we found that 54\% of individuals with one of the 4 CNVs who did not meet full autism diagnostic criteria nonetheless had elevated levels of autistic traits.Conclusion Many CNV carriers do not meet full diagnostic criteria for autism, but nevertheless meet clinical cut-offs for autistic traits. Although we find profile differences between variants, there is considerable variability in clinical symptoms within the same variant.Competing Interest StatementJH reports grants from Wyeth, Pfizer, AbbVie, A\&Z Pharmaceutical, and Takeda Pharmaceuticals outside of the submitted work. MJO and MBMvdB report grants from Takeda Pharmaceuticals outside of the submitted work. All other authors declare no competing interests.Funding StatementThis study was funded by the Baily Thomas Charitable Trust (MBMvdB, 2315/1), the Waterloo Foundation (MBMvdB, WF918-1234), Wellcome Trust ISSF grant (MBMvdB), the National Institute for Mental Health (MBMvdB, 5UO1MH101724; WRK, NIH / MH064824; CEB, RO1 MH085953; CEB and DMM-M U01MH101719; DMM-M U01MH087636), Medical Research Council studentship (SJRAC, 1499282), Wellcome Trust Fellowship (JLD, 505714), Wellcome Trust Strategic Award (MJO, 503147), Health \& Care Research Wales (MJO, Welsh Government, 507556), Medical Research Council Centre grant (MJO, G0801418), Medical Research Council Programme grant (MJO, G0800509), the Simons Foundation (CEB, SFARI Explorer Award), Brain Canada foundation (SJ), Canadian Institute of Health Research (SJ, 400528 /159734, Canadian Institute of Health Research (SJ), Canada Research Chair in Genetics of Neurodevelopmental Disorders (SJ), Simons Foundation Autism Research Initiative (WKC), Swiss National Science Foundation (AM, grant PMPDP3_171331), UK Medical Research Council and Medical Research Foundation grants (IMAGINE-ID study MBMvdB, JH \& MJO; MR/L011166/1 and MR/N022572/1), and the collaboration with the University of Belgrade was funded by the European Cooperation in Science and Technology (MM, MBMvdB, SJRAC; COST action, CA16210). The authors thank the main funders of the Autism Genome Project: Autism Speaks (USA), the Health Research Board (Ireland; AUT/2006/1, AUT/2006/2, PD/2006/48), the Medical Research Council (UK), the Hilibrand Foundation (USA), Genome Canada, the Ontario Genomics Institute, and the Canadian Institutes of Health Research (CIHR).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to ethical restrictions, data is not available to be shared.}, URL = {https://www.medrxiv.org/content/early/2020/10/05/2020.01.14.20017426}, eprint = {https://www.medrxiv.org/content/early/2020/10/05/2020.01.14.20017426.full.pdf}, journal = {medRxiv} }